4.7 Article

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin

Related references

Note: Only part of the references are listed.
Article Oncology

Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy

Ryuhei Okada et al.

Summary: This study compared the effects of Panitumumab and Cetuximab in APCs for NIR-PIT and the impact of different light exposure regimens on tumor growth in an immunocompetent mouse model. The results showed that APCs with longer half-life and double light exposure had superior outcomes in cancer cell-targeted NIR-PIT.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Biochemistry & Molecular Biology

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Johanna Theruvath et al.

Summary: The combination of anti-GD2 and CD47 blockade demonstrates robust anti-tumor activity in mouse models, particularly effective against neuroblastoma, osteosarcoma, and small-cell lung cancer.

NATURE MEDICINE (2022)

Article Oncology

CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model

Aki Furusawa et al.

Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a promising cancer treatment that combines antibody-photoabsorber-conjugate (AbPC) and NIR light. It is effective for surface-located skin cancers such as melanoma. The study found that CD29-targeted NIR-PIT showed better tumor growth inhibition and when combined with anti-CTLA4 checkpoint inhibitor, it resulted in improved immune response and prolonged survival.

ONCOIMMUNOLOGY (2022)

Article Oncology

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

Martin J. Edelman et al.

Summary: The combination of dinutuximab/irinotecan did not show improved overall survival in patients with relapsed/refractory small cell lung cancer (SCLC) compared to irinotecan alone. Irinotecan administered every 21 days demonstrated comparable activity to topotecan administered daily x 5 every 21 days.

LUNG CANCER (2022)

Article Otorhinolaryngology

Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

David M. Cognetti et al.

Summary: This study demonstrated the safety and efficacy of RM-1929 photoimmunotherapy in treating patients with rHNSCC. The treatment was well tolerated and showed clinically meaningful responses and survival outcomes in heavily pretreated patients, warranting further investigation.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2021)

Article Medicine, Research & Experimental

Fluorescence Imaging of Tumor-Accumulating Antibody-IR700 Conjugates Prior to Near-Infrared Photoimmunotherapy (NIR-PIT) Using a Commercially Available Camera Designed for Indocyanine Green

Fuyuki F. Inagaki et al.

Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that utilizes specific wavelength near-infrared light to target tumor cells for treatment. Research has shown that conjugation of a second near-infrared dye prior to NIR-PIT can provide real-time feedback on tumor location.

MOLECULAR PHARMACEUTICS (2021)

Review Nanoscience & Nanotechnology

Near infrared photoimmunotherapy of cancer; possible clinical applications

Hiroaki Wakiyama et al.

Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that selectively kills cancer cells using targeting monoclonal antibodies and photoactivatable phthalocyanine-derivative dyes, leading to minimal damage to patients and rapid recovery. Additionally, it activates host antitumor immunity and enhances nanodrug delivery to tumor beds.

NANOPHOTONICS (2021)

Article Oncology

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells

Stanley Ly et al.

Summary: GD2 is expressed in around 60% of primary TNBC tumors at variable levels and is associated with worse overall survival of patients with TNBC. Treatment with dinutuximab significantly decreased adhesion and migration of TNBC cells, inhibited mTOR signaling, and reduced tumor growth in both cell-line xenografts and PDX models. Our data provide proof-of-concept for the critical role of GD2 in BCSCs and demonstrate the potential of dinutuximab as a novel therapeutic approach for TNBC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma

Makoto Tahara et al.

Summary: The study evaluated the safety and efficacy of RM-1929 photoimmunotherapy in Japanese patients with rHNSCC, showing a manageable safety profile and clinically meaningful tumor response in some patients.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)

Review Biochemistry & Molecular Biology

Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy

Sophie Groux-Degroote et al.

Summary: Aberrant expression of glycosphingolipids is closely linked with malignant properties of cancer cells, making them targets for immunotherapy. Various strategies, including monoclonal antibodies, vaccines, and immune effector-cell therapy, have shown promising results in targeting these tumor-associated gangliosides. Adoptive cellular therapy with engineered T cells expressing chimeric antigen receptors is a particularly focused approach in this field.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Oncology

Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy

Takuya Kato et al.

Summary: NIR-PIT utilizes an antibody-photoabsorber conjugate activated by NIR light to selectively kill cancer cells with minimal damage to normal cells, while also inducing a therapeutic host immune response. This approach has great potential in treating a variety of cancers and can be used in combination with other immunotherapies for enhanced effect.

CANCERS (2021)

Article Medicine, Research & Experimental

Cadherin-17 Targeted Near-Infrared Photoimmunotherapy for Treatment of Gastrointestinal Cancer

Yick-Liang Lum et al.

MOLECULAR PHARMACEUTICS (2020)

Review Oncology

New era of research on cancer-associated glycosphingolipids

Koichi Furukawa et al.

CANCER SCIENCE (2019)

Article Oncology

CD47-Targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer

Bernhard Kiss et al.

CLINICAL CANCER RESEARCH (2019)

Review Chemistry, Multidisciplinary

Near-Infrared Photoimmunotherapy of Cancer

Hisataka Kobayashi et al.

ACCOUNTS OF CHEMICAL RESEARCH (2019)

Review Nanoscience & Nanotechnology

Enhanced nanodrug delivery in tumors after near-infrared photoimmunotherapy

Fuyuki F. Inagaki et al.

NANOPHOTONICS (2019)

Article Oncology

Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT

Tadanobu Nagaya et al.

MOLECULAR CANCER RESEARCH (2017)

Article Multidisciplinary Sciences

Phototheranostics of CD44-positive cell populations in triple negative breast cancer

Jiefu Jin et al.

SCIENTIFIC REPORTS (2016)

Review Biochemistry & Molecular Biology

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

Mahiuddin Ahmed et al.

FEBS LETTERS (2014)

Article Medicine, Research & Experimental

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis

Venkata Lokesh Battula et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Article Biochemistry & Molecular Biology

Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules

Makoto Mitsunaga et al.

NATURE MEDICINE (2011)

Article Medicine, General & Internal

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.

Alice L. Yu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Biochemistry & Molecular Biology

O-Acetylation of GD3 Prevents its Apoptotic Effect and Promotes Survival of Lymphoblasts in Childhood Acute Lymphoblastic Leukaemia

Kankana Mukherjee et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2008)

Article Multidisciplinary Sciences

Expression of Globo H and SSEA3 in breast cancer, stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis

Wen-Wei Chang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Biochemistry & Molecular Biology

Role of tumor-associated gangliosides in cancer progression

S Birklé et al.

BIOCHIMIE (2003)